Sussex Health Care is an amazing senior living facility. Sussex Health Care has several facilities located throughout the UK. Sussex Health Care has been doing an great job under Shiraz Boghani’s leadership. Shiraz Boghani is the chair man of Sussex Health Care Facility.
Sussex Health Care just made an expansion to their group of senior living facilities. They just added an audiology department to their group of homes. The audiology centers can be found at their Surrey, Sussex and Berkshire locations. Even though these centers are new to the Sussex Health Care clan, they are doing extremely well. Patients and residents are really satisfied with the results that they have been receiving from the center.
The Sussex Health Care Facility has been licensed by Royal College of Physicians. They have also been accredited by the United Kingdom Accreditation Service. Sussex Health Care is only one of few facilities that is actually accredited throughout the entire country. This is a huge plus, this ensures that all patients and future patients will be given nothing but the best professional care.
Read more: Sussex Healthcare Excels in Meeting Complex Nursing Home Challenges
Sussex Health Care’s Audiology services has given patients more confidence about their daily lives. Patients have came forth and stated that these audiology services has restored their hearing, confidence, and overall ability to be independent again.
At Sussex Health Care Audiology, they make sure that patients are given accurate test results from all of the diagnostic test that are given to patients. With hearing aids, sometimes patients aren’t able to hear even after they’ve received the hearing aids because they’ve been given the wrong results.
At Sussex Health Care that is impossible because all staff have received detailed training before and even during being employed with the facility. Sussex Health Care Facility provides health care services for many different kinds of health disorders. There are many specialist their for each condition. Sussex provides diverse care for all of the different needs that they encounter on a daily basis. Sussex aims to provide hearing aids that are effective for their patients. They also have a goal of proving patients with an excellent experience!
Prostate cancer is regularly diagnosed in men of all ages. In order to spread awareness of regular testing and education of this deadly disease, Cancer Treatment Centers of America (CTCA) is paring up with LabCorp and the National Football League Alumni Association (NFLA) to bring a series of events named “Prostate Pep Talk” to each of the CTCA’s locations featuring alumni and current players of the NFL. These events are designed to raise awareness that regular testing and education is necessary to optimal prostate health.
Along with the educational events, LabCorp is offering free screenings to the first 2,000 men who signed up for a PSA (Prostate Specific Antigen) test. PSA testing can indicate an anomaly within the prostate if testing comes back abnormal. When the 2,000 spots get filled up, LabCorp is offering a low cost fee of $25.00 for the PSA to be performed. Patient’s need to schedule the test within six months to still be eligible for the free or reduced price spots.This latest joint venture is a sign of CTCA’s commitment to patient care excellence.
Based in Boca Raton, Florida, CTCA has been offering cutting edge cancer care to it’s patients across the nation. There are five current facilities: Philadelphia, Atlanta, Chicago, Tulsa, and Phoenix that make the same commitment to treat the patient as a whole being: mind, body, and soul.CTCA offers the best in treatments including: precision cancer treatment, surgery, immunotherapy, chemotherapy, radiation, and genome testing. CTCA takes care of their patients from day one, offering supportive therapies for those going through treatment. CTCA even provides aftercare when a patient has completed their cancer treatment program. To read more about CTCA’s latest venture.
Based in Cranbury, New Jersey, Amicus Therapeutics is an American company that deals with biopharmaceuticals. The firm has developed advanced therapies to address rare and orphan diseases. Having gone public with its IPO in 2006 at NASDAQ Stock Exchange, the company has over the years developed a spectrum of treatment approached to address a variety of devastating human genetic problems.
With ATB200/AT2221 as their forefront biologics, which is a uniquely designed intervention for Pompe disease and applied alongside a pharmacological chaperone, Amicus Therapeutics has carved out a niche in the field of treating orphan diseases.
Migalastat, one of the company’s most robust interventions, is designed as an intervention for individuals suffering from late stages of Fabry disease in line with the patient’s genetic diagnosis. Another product candidate for late-stage development, SD-101, is a potential milestone therapy, the first-of-its-kind to treat the not so common connective tissue disease Epidermolysis Bullosa. Taking advantage of their biologics and utilizing the platform technologies of the Brandy Chaperone Advance Replacement Therapy, abbreviated as CHART, to develop new Enzyme Replacement Therapy interventions for the Pompe disease, Fabry disease, and similar lysosomal storage disorders. Know more on gcreport.com about Amicus Therapeutics.
Amicus Therapeutics got praised in 2004 as having possibly the broadest and most advanced portfolio of small molecules category of pharmacological chaperones. It was in 2008 when the company made a significant milestone in opening a new research center in San Diego to add to the one at New Jersey. Five years later Amicus would effect the acquisition of a rival company Callidus Biopharma which was a significant breakthrough especially in the development of the enzyme therapy intervention for the Pompe disease.
For 947 million dollars, the firm would acquire another of its competitors less than two years later, further advancing its dominance in the sector. John F. Crowley is both the CEO and the chairman of the board. Follow Amicus Therapeutics on Twitter.
Life Line Screening Company was founded in 1993 by Colin Scully and Timothy Phillips and is based in Austin, TX. It is a prevention and wellness company that is privately owned and operates health screening services that are community-based for adults across the USA. The company has conducted over eight million health screenings since it was founded, and it does over one million screenings per year. They carry out blood screenings, ultrasound scans, and electrocardiographs. The screenings are important because they ensure that diseases such as peripheral arterial disease, atrial fibrillation, and abdominal aortic aneurysm are detected early. The Better Business Bureau has accredited it since October 1996.
Their ultrasound screenings are painless and non-invasive, which is the same with their EKG for atrial fibrillation. When going for some screenings, you do not have to prepare much as compared to some screenings that require several hours of fasting while others require loose clothing or short sleeves only. Screening for Carotid artery disease requires the patient to wear a short-sleeved shirt that is open at the collar. Atrial fibrillation screening requires the patient to wear a two-piece outfit consisting of loose clothing, keep the cell phone turned off and do not wear pantyhose, watch or lotion or oil. Abdominal aortic aneurysm requires a two-piece outfit with loose clothing, fasting for four hours before the screening. However, for diabetic patients, they should stick to the recommended diabetic meal.
Ankle-brachial index screening requires the patient to wear a comfortable two-piece outfit with loose clothing, short-sleeved shirt or blouse and not to wear pantyhose. Complete lipid panel screening and glucose screening require fasting for eight hours before testing. 6 for life package require eight hours fasting before the screening, and the patient should wear a short-sleeved shirt. Bone mineral density patient only needs patient not to wear pantyhose. Patients going for elevated liver enzyme screening and hs-CRP(C-reactive protein) screening should not do anything in advance.
A board-certified physician reviews each screening apart from the 6 for life package as it is run through a clinically based predictive program. The patients receive a detailed report of their results within 21 days of their appointment through email or their online e-results program. Results are unique to the patient and signed by the reviewing physician and their National Medical Director. If a condition requires urgent attention, they inform the patient immediately. They also keep track of past screening history and remind the clients when it’s time to be re-screened.
To know more visit @: www.lifelinescreening.com/What-We-Do